CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Multibagger stock: Aarti Drugs locks in at upper circuit
Geyatee Deshpande
/ Categories: Trending, DSIJ Academy

Multibagger stock: Aarti Drugs locks in at upper circuit

On Monday, the shares of Aarti Drugs locked in at its upper circuit of 5 per cent at Rs 850.60 per share. The shares of Aarti Drugs locked in at its upper circuit consecutively for the third trading session thus, making this, its longest gaining streak of around 15.75 per cent in a month.

The stock is said to be a multibagger stock in the times of the Coronavirus crisis as it has gained by more than 600 per cent since March 2020. The stock has sky-rocketed by almost 625 per cent, recovering from its 52-week low of Rs 105.56 per share made on March 19, 2020. Since then, it has continued to have a strong upward trend. Thus, those investors, who entered in this quality stock in January 2020, have received huge appreciable returns.

The company had recently announced of bonus issue and had fixed October 1, 2020, as the record date to determine the eligible shareholders entitled to receive bonus shares. Outlining the details, three bonus equity shares would be issued for each share held (3:1).

Aarti Drugs reported a strong financial performance for Q1FY21 with a 280.62 per cent rise in net profit to Rs 85.45 crore for Q1FY21 against the net profit of Rs 22.45 crore gained in Q1FY20.

Aarti Drugs is a pharmaceutical company, having a strong presence in the anti-diarrhea, anti-inflammatory therapeutic groups. The company is involved in the manufacturing of vitamins, anti-arthritis, anti-fungal, antibiotics, ACE inhibitors as well as anti-diabetic, anti-cholinergic, sedatives, and anti-depressant drugs.

The stock of the company has gained by more than 20 per cent in a month and by almost 450 per cent on a YTD basis. The stock touched its 52-week high of Rs 931.13 per share on August 28, 2020.

Previous Article Franklin Templetons six shut funds receive Rs 8,262 crore
Next Article Infosys surges 3 per cent on completing acquisition of GuideVision
Print
8206 Rate this article:
3.5
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR